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SUMMARY
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For the past decade, cancer genomic studies have focused on mutations leading to splice-site
disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic
tool, MiSplice, for the large-scale discovery of splice-site-creating mutations (SCMs) across 8,656
TCGA tumors. We report 1,964 originally mis-annotated mutations having clear evidence of
creating alternative splice junctions. TP53 and GATA3 have 26 and 18 SCMs, respectively, and
ATRX has 5 from lower-grade gliomas. Mutations in 11 genes, including PARP1, BRCA1, and
BAP1, were experimentally validated for splice-site-creating function. Notably, we found that
neoantigens induced by SCMs are likely several folds more immunogenic compared to missense
mutations, exemplified by the recurrent GATA3 SCM. Further, high expression of PD-1 and PDL1 was observed in tumors with SCMs, suggesting candidates for immune blockade therapy. Our
work highlights the importance of integrating DNA and RNA data for understanding the functional
and the clinical implications of mutations in human diseases.

In Brief
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Jayasinghe et al. identify nearly 2,000 splice-site-creating mutations (SCMs) from over 8,000
tumor samples across 33 cancer types. They provide a more accurate interpretation of previously
misannotated mutations, highlighting the importance of integrating data types to understand the
functional and the clinical implications of splicing mutations in human disease.

INTRODUCTION

Author Manuscript

Large-scale sequencing studies, such as The Cancer Genome Atlas (TCGA) project, have
worked to address the functional consequences of genomic mutations in tumors (Dees et al.,
2012; Kandoth et al., 2013; Lawrence et al., 2013; Niu et al., 2016), with the larger goal of
determining the underlying mechanisms of cancer initiation and progression. Many studies
have focused on characterizing (1) non-synonymous somatic mutations that alter amino acid
sequence and (2) splice-disrupting mutations at splice donors and acceptors (Jung et al.,
2015). Current annotation methods typically classify mutations as disruptors of splicing if
they fall on either the consensus intronic dinucleotide splice donor, GT, or the splice
acceptor, AG. As a group, splice site mutations have been presumed to be invariably
deleterious because of their disruption of the conserved sequences that are used to identify
exon-intron boundaries.

Author Manuscript

While this classification method has been useful, increasing evidence suggests that splice
site mutations can lead to transcriptional changes beyond disruption of the canonical
junction (Lim and Fairbrother, 2012; Mort et al., 2014; Rivas et al., 2015; Sauna and
Kimchi-Sarfaty, 2011; Steffensen et al., 2014). One such example is the c.190 mutation in
BRCA1. Conventional annotation had predicted a missense mutation, p.C64G, but our
analysis of RNA sequencing (RNA-seq) data in ovarian tumors harboring p.C64G and a
published mouse model (Yang et al., 2003) suggested the germline c.190 mutation leads to
the creation of an alternative splice junction, resulting in a truncated null protein. Several
case studies have reported observations of missense and silent mutations activating cryptic
splice sites in MLH1 (Nyström-Lahti et al., 1999), LMNA (Woolfe et al., 2010), RB1
Cell Rep. Author manuscript; available in PMC 2018 July 23.
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(Zhang et al., 2008), RNASEH2A (Rice et al., 2013), MECP2 (Sheikh et al., 2013), BAP1
(Wadt et al., 2012), and KIT (Chen et al., 2005), and other studies relate missense and silent
mutations to splicing changes (Jung et al., 2015; Kahles et al., 2016; Soemedi et al., 2017;
Supek et al., 2014). Despite the broad clinical ramifications of mutation-induced altered
splicing, a systematic evaluation of their occurrence and the resultant effects in cancer has
yet to be undertaken, and there have not been significant bioinformatics platforms for doing
so.

Author Manuscript

We developed a bioinformatic tool called MiSplice (mutation-induced splicing) that
integrates DNA and RNA-seq data across thousands of samples to discover mutations that
induce splice site creation. In our large-scale analysis across 8,656 tumor samples, we report
1,964 such somatic mutations that had originally been mis-annotated. Splice-site-creating
mutations (SCMs) are enriched in the new introns, with the highest rate at the −3 nt position
of acceptors with two-thirds of such events at aGag and agGag repeats by creating an
alternative junction 2 nt away. Partial and full splice creation capabilities across these 1,964
sites were evaluated by measuring the fraction of reads supporting the alternative junction,
which we termed the ‘‘junction allele fraction’’ (JAF) and which is found to be negatively
correlated with distance to the new splice site. In total, 1,607 genes harbor SCMs, with 248
of them having more than one mutation, including TP53, GATA3, ATRX, and NF1.
Recurrent SCMs were found in TP53, GATA3, DDX5, KDM6A, PTEN, SETD2, SMAD4,
BCOR, SPOP, and BAP1, suggesting an association with cancer development. Broadly
speaking, integrated DNA and RNA data can furnish a sound basis for discovering SCMs
and for accurately understanding functional consequences of mutations in cancer and in
other human diseases.

Author Manuscript

RESULTS
Splice-Site-Creating Mutation Discovery
We collected high-quality mutation calls from 8,656 tumors across 33 cancer types derived
from The Cancer Genome Atlas having available TCGA RNA-seq data (STAR Methods).
For every mutation, we defined a set of control samples in the same cancer cohort that
lacked the same mutation in the gene of interest. We sought to assess the landscape of SCMs
across cancer genomes by evaluating all mutations already having conventional annotations
and their potential splice-site-creating effects (Figure 1A). To achieve this goal, we
conducted analysis using a bioinformatic tool, MiSplice (mutation-induced splicing), that
systematically evaluates mutations in a splicing context using RNA-seq data (Figure 1B).

Author Manuscript

MiSplice manages large analyses using parallel computation to search for alternative splice
junctions within windows of ±20 bp from the mutation of interest. For example, of the
1,416,566 candidate mutations examined here, 4,448 had five or more unique RNA-seq
reads supporting the predicted alternative junction in proximity to the mutation. MiSplice
then conducts a series of further evaluations, including Ensembl-based filtering of canonical
junctions, establishing observational significance by case comparison to a matched set of
controls, and assessing score and depth of each cryptic site using MaxEntScan (Yeo and
Burge, 2004) and SamTools (Li et al., 2009). From the resultant subset, MiSplice filters out
human leukocyte antigen (HLA) genes and sites whose junctions have insufficient difference
Cell Rep. Author manuscript; available in PMC 2018 July 23.
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of expression, as judged from the case-control assessment. Here, we evaluated promising
alternative junctions with at least 5% of paired-end RNA-seq reads at the genomic location
supporting the alternative junction of interest.
MiSplice processing revealed 2,056 mutations (Table S1) that potentially create an
alternative splice site. Manual review indicated a 2.09% false-positive rate, suggesting high
specificity of the MiSplice algorithm for discovering these types of mutation-induced
splicing events. Of these putative splice events, 1.90% and 0.47% are considered complex
and are in highly homologous gene regions, respectively, so they were excluded from further
analyses (STAR Methods).

Author Manuscript

Of the final 1,964 SCMs passing manual review (Table S1), 52% (1,016) are in annotated
splice sites, suggesting disruption of the canonical splice site and selection of a the
alternative splice site nearby (Figure 1C). Importantly, 26% (513) and 11% (208) of the
SCMs had previously been mis-annotated as missense and silent mutations, respectively. In
addition, we found 58 insertions or deletions, 46 nonsense, and 123 non-coding region
mutations that likewise create cryptic splicing sites.
Molecular and Biological Patterns of SCMs
Next, we characterized the sequence context for the 1,790 SCMs corresponding to single
nucleotide mutations. The sequences of each 9-mer (donor) and 23-mer (acceptor) covering
the mutation position were extracted for both the mutant and the reference sequences. Their
splice scores as potential donor or acceptor sites were then estimated using MaxEntScan
(Table S1).

Author Manuscript
Author Manuscript

Mutations near the alternative splice junctions show higher mutation rates in the introns for
both 5′ (p < 1 × 10−5, binomial test) and 3′ splice site (p < 1 × 10−6) (Figure 2A). More
interestingly, we found an enrichment of mutations at the third nucleotide position in the
intron, but depletion at the first and second positions (especially for 3′ splice site) (Figure
2A). Comparison of splicing scores between splice-site-creating mutants and reference
forms shows that most mutants have stronger splice signals than the reference (Figure 2B).
Mutations that create a G or T to produce an alternative 5′ splice site dramatically increase
splice site strength. For 3′ splice sites, mutations enriched on the third nucleotide of the
newly created intron showed the largest increase of splicing score (Figure 2B). Further
examination of the sequence context around mutations at the third nucleotide of 3′ splice
sites shows that 53% have a mutation on aGag repeats and another 16% are mutated on
agGag repeats, all creating alternative junctions 2 nt away from the annotated ones (Figure
2C). Mutations at the −3 position of the alternative acceptor site would potentially enhance
U2AF1 recognition of the acceptor splice site. Previous studies have reported S34F U2AF1
mutants preferentially skip exons that contain a T nucleotide at the −3 position (OkeyoOwuor et al., 2015). Of the 192 mutations located at the −3 position from the alternative
junction and that contain an AG in the −2 and −1 positions, 56% undergo a G > C
transversion (21%G > A, 18%G > T,3%C > T,2%A > C, 1% A > T), with C being the
preferred base at the −3 position for U2AF1 binding (Figure 2D).

Cell Rep. Author manuscript; available in PMC 2018 July 23.
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We also explored the relationship between the alternative and canonical splice junctions. As
expected, mutations at splice sites dramatically reduced splice scores of the canonical splice
junctions, while strengthening those at the alternative splice junctions in most cases. In
contrast, a subset of missense and silent mutations did not drastically alter the canonical
junction, but instead preferentially strengthened a nearby alternative splice site (Figure 2E).
When analyzing the raw splicing scores (canonical and alternative site before and after
mutation), we found that 1,089 out of 1,790 (61%) events showed higher splice score for the
alternative splice site than the canonical site, indicating inclination for the alternative sites.
Further, while 485 (27%) events saw lower post-mutation alternative splice score,
differences between alternative and canonical scores had decreased, suggesting that these
mutations are still likely enhancing the preference for the alternative site. Only 214 (12%)
events did not show evidence, suggesting increased post-mutational preference for using the
alternative site. These cases are a good illustration of the fact that many other genomic
splicing features are also relevant, including exonic splicing enhancers (ESE),
polypyrimidine tract, branch point, and RNA-binding proteins. They are also consistent with
the general view that splice score is not definitive (Jian et al., 2014). We emphasize that all
1,790 alternative splice sites demonstrated usage based on patient RNA-seq data and that 10
out of 11 (>90%) identified SCMs were validated experimentally (see below).
Expressivity and Penetrance of SCMs

Author Manuscript

In the presence of the mutation, alternative splice junctions exhibited a wide range of
expression. To quantify this effect, we measured alternative junction expression as the
fraction of alternatively spliced junction spanning reads over the total number of reads at the
genomic location, what we refer to as the JAF. Figure 3A shows the distribution of JAF’s for
all high confidence MiSplice predicted alternative junctions, separated by conventional
mutation annotations (Figure 3A). Currently, we use a JAF cutoff of 5% for reporting the
final high-confidence sites. However, there are some potential alternative sites excluded by
this cutoff. Our analysis revealed alternative junction expression varies widely. As expected,
DNA variant allele fraction (VAF) and JAF have a generally positive correlation (Figure 3B),
with SCMs in KDM6A and FGFR2 having >75% DNA VAF and JAF. However, a SCM in
ARID1A has a DNA VAF of 23% and JAF of 67%. Such large ranges have been noted for
mutations outside of the splice site (Broeks et al., 2003; Clarke et al., 2000; Venables, 2004).
Both the truncated and normal spliced products can be observed for many variants, due to
either the wild-type allele or leaky splicing, for example, as observed in RNASEH2A,
NFU1, SMN1, CFTR, and NF2 (Boerkoel et al., 1995; Caminsky et al., 2014; Ferrer-Cortès
et al., 2016; Lohmann and Gallie, 2004; Mautner et al., 1996; Pagani et al., 2003; Rice et al.,
2013; Svenson et al., 2001; Vezain et al., 2011).

Author Manuscript

Next, we considered the expression of mutations that are spliced-in, i.e., mutations located
within the exon of the alternatively spliced product. To this end, we determined the ratio of
the number of alternative junction reads containing the mutation versus total number of
reads supporting the alternative junction (Figure 3C; Table S1). Overall, most of the reads
supporting the alternative junction also support the mutation, a finding that suggests a strong
association between the mutation and alternative splice junction. Regarding the 5′ splice
site, mutations within the first 6 bp of the new exon junction have a much higher fraction of
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alternative junction reads supporting them; and we see an inverse correlation between the
mutation and the junction as the distance between them increases. For the 3′ splice site, we
observe a similar trend, although with a higher variability as a function of the distance from
the alternative junction.
SCMs across Genes and Cancer Types

Author Manuscript

A total of 1,607 unique genes harbored SCMs, with 85% (1,359) having one mutation and
15% (248) having two or more. TP53 contained the greatest number (26), followed by
GATA3 (18). While most SCMs were found outside the current cancer gene compendium
(Table S1), Figure 4A shows that a remarkable number of cancer genes harbor splice altering
variants, a phenomenon supported in the literature (Sebestyén et al., 2016). A pan-cancer
view reveals that TP53 was the most mutated across cancer types, while 18 GATA3
mutations and 6 ATRX mutations were specific to breast cancer (BRCA) and lower-grade
glioma (LGG), respectively.
We observed 137 mutations nearby to one another (±5 bp) which lead to the creation of the
same recurrent splice-site-creating events, not only in TP53 but also in GATA3, DDX5,
KDM6A, SETD2, PTEN, SPOP, and BAP1. While some mutations did not occur at the
same position, 14 mutations creating the same alternative splice junction were found in the
same exon, including 2 mutations in the third exon of BAK1. While most mutations in close
proximity created the same alternative splice junction, two adjacent SCMs in CTNND1 and
2 nearby exonic mutations in ACP2 and GMPPB created different alternative junctions.

Author Manuscript
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SCMs can impact protein structure and have potential therapeutic implications. Poly ADPribose polymerase 1 (PARP1) is an enzyme involved in recruiting protein members of DNA
repair pathways including Timeless PAB (PARP1 binding domain) (Figure 4C) (Xie et al.,
2015). Since PARP1 is essential to many cellular processes, including DNA repair, it is
commonly targeted by antitumor agents (Malyuchenko et al., 2015). PARP1 inhibitors
targeting the catalytic domain disrupt DNA repair mechanisms thereby increasing the
effectiveness of chemotherapeutic agents (Figure 4D). Identifying mutations that disrupt
inhibitor binding are essential to properly evaluate treatment options. MiSplice identified a
conventionally annotated silent PARP1 mutation (p.S939S) in a lung squamous cell
carcinoma (LUSC) patient that acts as a splice-site-creating variant by creating a de novo
donor site (Figure 5A). 82 reads supported the de novo donor site, which results in a 10
amino acid deletion (p.940–p.950) that falls within the catalytic domain (Figure 4D). Out of
173 LUSC control samples, none contained reads supporting the alternative junction,
providing strong evidence that the annotated ‘‘silent’’ mutation is actually a SCM. Previous
reports of missense mutations at p.940 are predicted to reduce PARP1 enzymatic activity by
disrupting the binding affinity of PARP1 to its substrate NAD+ (Alshammari et al., 2014).
The in-frame SCM likely disturbs the local structure of PARP1 and thereby disrupts the
interactions between PARP1, its protein binding partners, and drugs binding within the
pocket (Figures 4C and 4D).
We identified two kidney renal clear cell carcinoma (KIRC) samples having the same
conventionally annotated missense mutation (c.233A > G, p.N78S) in BAP1, a nuclear
deubiquitinase, that created the same spliced-out alternative splicing product (Figure 5B).
Cell Rep. Author manuscript; available in PMC 2018 July 23.
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Inactivation of BAP1 is prevalent among renal cell carcinomas (Peña-Llopis et al., 2012) and
an annotated missense mutation (p.L570V) has been reported to create a cryptic splice site in
melanoma (Wadt et al., 2012). At the transcriptional level, the expressions of the case and
control samples are relatively comparable, but at the translational level, one case with
available protein data (RPPA) showed significantly lower expression (p = 0.044, permutation
test) relative to the controls (Figure S1; Table S2). This result suggests the conventionally
annotated missense mutations in BAP1 likely create an alternatively spliced transcript that is
not readily expressed at the protein level.

Author Manuscript
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We used a pCAS2.1 splicing reporter mini-gene functional assay that was adapted from
previous publications (Bonnet et al., 2008; Gaildrat et al., 2010; Malone et al., 2016;
Tournier et al., 2008; Vreeswijk and van der Klift, 2012), to validate SCMs in 11 cancer
genes, including two originally annotated silent mutations in PARP1, RAD51C, two splice
site mutations in TP53 and BRCA1, and several missense mutations in ARID2, BAP1,
BCOR, CDH1, KMT2A, PTEN, and TSC2. Wild-type and mutant exons were cloned into a
pCAS2.1 vector (Gaildrat et al., 2010) and transiently transfected into HEK293T cells. Total
RNA was extracted to evaluate alternatively spliced products by RT-PCR. Examining the
change in the MaxEntScan score for the 11 genes revealed mutations in ARID2, BAP1,
BCOR, CDH1, PARP1, RAD51C, PTEN, and TSC2 having dramatically stronger splice
scores in the presence of the mutation, while mutations in BRCA1, KMT2A, and TP53 did
not (Figure 5D). Except for PTEN, variants with stronger splice scores showed higher levels
of the alternatively spliced product in the mini-gene assay when compared to the wild-type.
Variants with moderate changes in splice score still showed evidence of alternatively spliced
transcripts, revealing the importance of utilizing functional assays to evaluate the effect of
mutations in a splicing context in addition to in silico predictions. The minigene assay
confirmed 91% (10/11 genes) splicing alterations in all tested genes and sequencing
confirmed the alternatively spliced products (Figure 5E; STAR Methods), suggesting a
strong concordance between MiSplice predicted SCMs and the functional assay.
Neoantigens Introduced by SCMs

Author Manuscript

We have further investigated neoantigens produced by SCMs. By using the RefSeq transcript
database, a total of 2,993 protein sequences were translated for transcripts containing
mutation-induced alternative splice forms (Table S3). In the translation, we allowed for
different transcripts from each SCM. The HLA types for each sample were adopted from the
TCGA pancan immune working group (Synapse ID: syn5974636). NetMHC4 and
NetMHCpan-3.0 (Andreatta and Nielsen, 2016) were used to predict the binding affinity
between epitopes and the major histocompatibility complex (MHC) and showed a high
concordance in total predicted neoantigens (Pearson = 0.94; Figure S2). We found that
alternative splice forms for some important genes related to tumorigenesis, including
SMARC1, KDM6A, and NOTCH1, are highly immunogenic and can contain 40 or more
unique neoantigens (Figure 6A) (Dalgliesh et al., 2010; Papadakis et al., 2015). In addition,
the mean number of neoantigens across SCMs from NetMHCpan-4.0 and NetMHCpan-3.0
are 2.0 and 2.5, respectively, which are both higher than the average number of around 1 for
non-synonymous mutations. Furthermore, 28 genes contain recurrent neoantigen events (≥3)
across samples (Figure 6B). In particular, GATA3 has the highest recurrence and GATA3
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SCMs were mutually exclusive with other mutation types (Figure 6C). The CA deletion at
chr8:8111433 disrupts the canonical splice site and an alternative splice site is used for
creating the alternative splice form, which results in a frame shifted protein product
spanning the Zinc-finger domain (Figures 6D and 6E). 19 unique neoantigen peptide
sequences were mapped to the frameshifted protein product for the 16 samples (Figure 6F).
We were further able to validate one alternative peptide sequence using mass spectrometry
data from a recent proteogenomics study on 77 TCGA breast cancer patients (Mertins et al.,
2016). For one sample with the highly recurrent and expressed GATA3 SCM, we used
MSGF+ to search publicly available mass spectrometry data for evidence of alternative
GATA3 peptides. Figure 6G shows one identified mass spectrum supporting one alternative
GATA3 peptide, which covers two immunogenic peptides (KPKRRLPG and
LIKPKRRLPG) predicted in TCGA-AR-A1AP.

Author Manuscript

High neoantigen burden is associated with an elevated immune response (Turajlic et al.,
2017). To test whether SCMs affect immune response, we compared the expression of T cell
markers PD-1, CD8A and CD8B and PD1 immune checkpoint blockades PD-L1 and PD-L2
(Figure 7). We selected six cancer types (BRCA, BLCA, HNSC, LUAD, LUSC, and
SKCM) with sufficient samples containing SCMs for adequate statistical power. Both T cell
markers (PD-1, CD8A, and CD8B) and immune checkpoint blockade PD-L1 show increased
expression in samples with SCMs compared to samples without SCMs (Figure 7), indicating
alternative splice forms induced by SCMs increase the overall immunogenicity of these
cancers. The highly expressed PD-L1 suggests PD-L1 immunotherapy as potential
treatments for samples containing SCMs.

DISCUSSION
Author Manuscript
Author Manuscript

In this study, we applied our newly developed bioinformatics tool called MiSplice
(mutation-induced splicing) to systematically analyze splice-site-creating events that arise
from somatic mutations. Our analysis shows MiSplice reliably identifies SCMs across
multiple cancer types. Existing studies have largely focused on splice-disrupting events in
known splice sites, but the current study substantially extends our knowledge into the realm
of SCMs in human cancer. For instance, we found 1,016 splice site mutations not only
disrupt the canonical splice site but also create an alternative splice site. We also found that
hundreds of mutations that would traditionally be classified as missense, silent, indel, and
nonsense are really acting as SCMs. Many important cancer-related genes harbor these
mutations, such as TP53, ATRX, BAP1, CTNNB1, RB1, etc. It is noteworthy that we found
five SCMs in ATRX among 288 LGG cases, likely leading to the disruption of ATRX
function. A previous study has shown that loss of wild-type ATRX is associated with tumor
growth in glioma (Koschmann et al., 2016).
Characterization of these alternative splice events show that most SCMs have a higher splice
score, as measured by MaxEntScan, in the post-mutation alternative splice site as compared
to the reference. These results are consistent with the preferential selection of these
alternative sites as new splicing forms. For the splice-site mutation, the splice score
associated with the canonical junction is coincidently decreased after mutation. However,
while there is no difference in splice scores of canonical junctions before and after missense
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and silent mutations, the alternative splice site was often strengthened after mutation. This
suggests silent and missense mutations instead act as modifiers of splicing by creating or
strengthening cryptic sites within the exon as opposed to disrupting the canonical splice site.
In addition, we found a significant enrichment of mutations at the −3 position in the 3′
splice site, the two dominant sequence contexts being aGag and agGag, where G is at the −3
position.
In cases in which the mutation is retained in the alternative splice junction, we distinguish
mutations with two further categories, splice-in and splice-out. For splice-in mutations, we
can characterize the association between mutations and cryptic splicing forms. For example,
we found high concordance for RNA-seq reads supporting alternatively spliced junctions
and mutations, suggesting the association between mutations and cryptic splicing forms.

Author Manuscript
Author Manuscript

The current study has greatly extended insights into the transcriptional ramifications of
genomic alterations by identifying nearly 1,964 alternative splice sites introduced by somatic
mutations and functionally validating 10 of 11 variants in a mini-gene splicing assay. These
events were conventionally annotated as missense, silent, splice site, nonsense, or other
mutations when, in fact, we have shown that they often create cryptic splice sites. This
relative abundance of the alternative and wild-type product suggests varying levels of
junction usage, depending on the context of the mutation, and emphasizes the importance of
validating predictions using a functional assay to understand the full biological consequence.
The alternative products may be therapeutically targetable in some cancer patients. For
example, targeting neoantigens shows promising results in treating melanoma patients
(Carreno et al., 2015). By further evaluating human leukocyte antigen (HLA) genotypes and
binding affinities to the MHC, it is likely that new neoantigens from cryptic splice sites may
be discovered. The current study reveals that alternative splice forms induced by SCMs are
highly immunogenic and correlated with a high T cell immune response and an elevated PDL1 expression, suggesting the potential for immunotherapy in these samples. Further
investigation of the cryptic splice sites by mass spectra or target assay are needed to
prioritize therapeutic targets in clinical trials.
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•

STAR★METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be
fulfilled by the Lead Contact, Li Ding (lding@wustl.edu).
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
The Cancer Genome Atlas (TCGA) collected both tumor and non-tumor biospecimens from
10,224 human samples (https://cancergenome.nih.gov/abouttcga/policies/informedconsent).
Here, we use variants from a publicly available mutation annotation file (MAF) complied by
the MC3 working group (syn7824274).
METHOD DETAILS

Author Manuscript

Dataset Description—Aligned RNA-seq bam files were analyzed using the ISB google.
These cancer types are Acute Myeloid Leukemia [LAML], Adrenocortical carcinoma
[ACC], Bladder Urothelial Carcinoma [BLCA], Brain Lower Grade Glioma [LGG], Breast
invasive carcinoma [BRCA], Cervical squamous cell carcinoma and endocervical
adenocarcinoma [CESC], Cholangiocarcinoma [CHOL], Colon adenocarcinoma [COAD],
Esophageal carcinoma [ESCA], Glioblastoma multiforme [GBM], Head and Neck
squamous cell carcinoma [HNSC], Kidney Chromophobe [KICH], Kidney renal clear cell
carcinoma [KIRC], Kidney renal papillary cell carcinoma [KIRP], Liver hepatocellular
carcinoma [LIHC], Lung adenocarcinoma [LUAD], Lung squamous cell carcinoma [LUSC],
Lymphoid Neoplasm Diffuse Large B cell Lymphoma [DLBC], Mesothelioma [MESO],
Ovarian serous cystadenocarcinoma [OV], Pancreatic adenocarcinoma [PAAD],
Pheochromocytoma and Paraganglioma [PCPG], Prostate adenocarcinoma [PRAD], Rectum
adenocarcinoma [READ], Sarcoma [SARC], Skin Cutaneous Melanoma [SKCM], Stomach
adenocarcinoma [STAD], Testicular Germ Cell Tumors [TGCT], Thymoma [THYM],
Thyroid carcinoma [THCA], Uterine Carcinosarcoma [UCS], Uterine Corpus Endometrial
Carcinoma [UCEC], Uveal Melanoma [UVM]
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MiSplice Pipeline—The MiSplice pipeline was developed to detect mutation-induced
splicing events from RNA-seq data. It is written in Perl and incorporates two standard tools,
samtools and MaxEntScan. The pipeline is fully automated and can run multiple jobs in
parallel on LSF cluster. It executes the following steps:
1.

Splitting large maf file into multiple smaller files with less mutations (currently,
the default setting is 200).
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2.

Discovering splicing junctions within 20bps of the mutation with at least 5
supporting reads with mapping quality Q20 and then filtering canonical junctions
by using the Ensembl 37.75 database. We selected 20bp as a cut-off since it is the
farthest distance from the splice junction in a splice region.

3.

Computing the number of supporting reads of above cryptic splice sites for
control samples without mutations (Table S1).

4.

Calculating the splicing scores for the cryptic splice sites via MaxEntScan.

5.

Reporting the depth of each cryptic splice site via Samtools.

6.

Filtering cryptic sites which fall in HLA loci or less than 5% of reads at the
genomic location supporting the alternative junction of interest.

7.

Further filtering cryptic sites by comparing the supporting reads in control
samples. The final reported cryptic sites must stand as top 5% for the number of
supporting reads in the case (with mutation).

Splice Site Score Estimation—For each cryptic splice site and nearby canonical splice
site, the corresponding nucleotide sequences were first extracted for both the mutant and
reference sequences (9-mer and 23-mer for donor and acceptor, respectively). Their splice
scores as potential donor or acceptor sites were then estimated using MaxEntScan.
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Neoantigen Prediction—For each predicted SCM, we use a curated RefSeq transcript
database (version 20130722) to obtain the translated protein sequences for transcript
containing alternative splice forms induced by SCMs. Different length of epitopes (8-mer, 9mer, 10-mer and 11-mer) are constructed from the translated protein sequence. We use
NetMHC3pan (Nielsen and Andreatta, 2016) and NetMHC4 (Andreatta and Nielsen, 2016)
to predict the binding affinity between epitopes and MHC. Epitopes with binding affinity ≤
500nM which are also not present in the wild-type transcript are extracted from the
following neoantigen analysis.
Manual Review—All splice-site-creating mutations were manually reviewed using the
integrative genomics viewer (http://software.broadinstitute.org/software/igv/). Mutations
were placed into one of three categories: Pass, Complex, and No Support. Mutations were
classified as complex if more than one alternatively spliced product was observed for the
mutated sample.
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Code Availability—MiSplice is written in Perl and is freely available from GitHub at
https://github.com/ding-lab/misplice under the GNU general public license. MiSplice uses
several independent tools and packages, including SamTools and MaxEntScan, all of which
are likewise freely available, but which must be obtained from their respective developers.
The MiSplice documentation contains complete instructions for obtaining and linking these
applications into MiSplice.
Mini-gene Splicing Assay—Exons of interest and approximately 150 bp of their
flanking intron sequences were PCR amplified from HEK293T genomic DNA using primers
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carrying restriction enzyme sites for BamH1 and MluI. PCR products were cleaned up using
NucleoSpin PCR Cleanup (Macherey-Nagel) or DNA Clean and Concentrator-5 Kit (Zymo
Research) and digested with BamHI and MluI. The digested pCAS2.1 vector and PCR
products were ligated using T4 DNA Ligase (NEB). Mutations were introduced via Q5 SiteDirected Mutagenesis (NEB). WT and MUT constructs were confirmed by sequencing of
the insert region. The plasmids were transiently transfected into HEK293T cells using
Lipofectamine 2000 (ThermoFisher Scientific). 24 hr post transfection, cDNA was
synthesized using 2 to 3 ug of total RNA with the Superscript III First-Strand Synthesis
System (ThermoFisher Scientific) and priming with Oligo(dT)20. Finally, cDNA was
amplified using pCAS-KO1-(5′-TGACGTCGCCGCCCATCAC-3′) and pCAS-R (5′ATTGGTTGTTGAGTTGGTTGTC-3′) and the alternative splicing patterns were evaluated
on a 2.5% agarose gel with ethidium bromide. Qiaquick Gel Extraction Kit (QIAGEN) was
used to purify bands for sequencing (Figures S3, S4, S5, and S6; Tables S5, S6, and S7).
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Cell Culture—HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with fetal bovine serum (FBS) and penicillin streptomycin.
QUANTIFICATION AND STATISTICAL ANALYSES

Author Manuscript

MiSplice assesses the significance of the number of reads supporting the predicted
alternative splice junction by comparing to read counts from a control cohort. Specifically, a
frequency distribution is constructed from the control cohort, from which threshold values
for 5% and 95% tails on the left and right, respectively, are determined. A series of logic
tests is then conducted to discern the best explanation of the data. Possible verdicts are low
or high expression if the datum is outside the 5% or 95% thresholds, respectively, average
expression if no thresholds are exceeded, or no expression in this tissue if the thresholds are
zero.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
•

MiSplice applied to PanCancer data identifies 1,964 splice-site-creating
mutations

•

26% and 11% of SCMs had been previously mis-annotated as missense and
silent mutations

•

SCMs may be more immunogenic than are missense mutations

•

A mini-gene functional assay validates 10 of 11 predicted SCMs
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Figure 1. Splice-Site-Creating Mutation Discovery
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(A) Examples of splice-site-creating mutations for different conventionally annotated
mutation types. Splice-in is defined as mutations contained within the newly created exons,
and splice-out is when the mutation is present in the newly created intron.
(B) The MiSplice workflow consists of three steps: alternative junction discovery, filtering,
and manual review. First, the user inputs the locations of RNA-seq BAM files along with a
mutation file. MiSplice searches the BAM file to identify any alternative splice junctions
near the mutation of interest, while filtering out known splice junctions and calculating the
number of alternative junction-supporting reads for case and control samples. For the
filtering step, the following sites are removed: mutations in HLA genes, a low fraction of
reads supporting the alternative splice junction, and sites expressed in controls. Finally, we
manually reviewed all sites to validate the in silico predictions.
(C) Breakdown of 2,056 manually validated splice-site-creating mutations by conventional
annotation.
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Figure 2. Sequence Contexts and Characteristics of Splice-Site-Creating Mutations
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(A) Frequency distribution of splice-site-creating mutations relative to the newly created
splice junction, with high frequency shown at the third nucleotide position in the newly
created intron.
(B) Comparison of splicing scores for the newly created splice site, before (reference) and
after the mutation (mutant). A larger effect of mutations at the third nucleotide position in
the intron (especially for the 3′ splice sites) is shown.
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(C) Dominant nucleotide sequence context for splice-site-creating mutations at −3 position
of the 3′ splice site. Mutation position (red dot) is present 3 base pairs away from the newly
created exon.
(D) Transition and transversion rate at the −3 position of the 3′ splice site. Most mutations
are G > C transversions, strengthening the consensus sequence of the splicing factor U2AF1.
(E) Comparison of splicing scores between the nearest canonical splice junction with and
without a mutation compared to the newly created splice junction with and without a
mutation. Most mutations strengthen the alternative splice junction relative to the canonical
splice junction.
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Figure 3. Junction Allele Fraction of Splice-Site-Creating Mutations
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(A) The junction allele fraction (JAF) is defined as the number of reads supporting the
alternative spliced junction relative to total junction spanning reads. Distribution of JAF
values separated by conventional annotation type.
(B) JAF versus DNA variant allele fraction (VAF) comparison by conventional annotation
type. Most mutation types show a generally positive correlation between JAF and VAF
values.
(C) Splice-site-creating mutations expressed in the newly created exon of the alternative
splice junction. Comparison of mutation position relative to the percent of reads supporting
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the alternative junction and mutation (spliced-in JAF). The mean of each position is
highlighted by the black point. For all positions, there is a strong correlation between the
presence of the splice-site-creating mutation and the alternative splice junction.
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Figure 4. Splice-Site-Creating Mutations across Genes and Cancer Types
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(A) Distribution of splice-site-creating mutations in each gene separated by the total number
of mutations in each gene. TP53 has the largest number of splice-site-creating mutations,
followed by GATA3 and ATRX.
(B) Genes with the highest number of pancancer splice-site-creating mutations. Circle size
correlates with the total number of mutations for each gene (labeled inside circle) and
colored by cancer type. Splice-site-creating mutations in TP53 are present in many cancer
types, while mutations in ATRX and GATA3 are specific to LGG and BRCA, respectively.
(C) Proteins Timeless (PAB domain) and PARP1 (chain A) are colored green and pink,
respectively. Originally annotated p.S939S mutation (red) and spliced-out sequence (blue)
are highlighted on PARP1 (chain A).
(D) 3D protein structure of PARP1 in complex with an inhibitor (PDB ID: 5WRQ). Drug
inhibitor and PARP1 (chain A) are indicated in green and pink, respectively.
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Figure 5. Minigene Functional Assay of Splice-Site-Creating Mutations
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(A) Integrative genomics viewer (IGV) screenshot of the conventionally annotated
synonymous mutation in PARP1 in exon 21. RNA-seq reads of the candidate splice-sitecreating mutation reveal the creation of an alternative splice site (red reads) created by the
conventionally annotated synonymous mutation.
(B) Candidate recurrent splice-site-creating mutations in BAP1. Conventionally annotated as
synonymous variants, the BAP1-mutated region shows alternatively spliced reads (red reads)
in the IGV screenshot for each sample with the splice-site-creating mutation.
(C) IGV screenshot of a conventionally annotated synonymous mutation in RAD51C in
exon 2.
(D) Maximum entropy score of the splice-site-creating variant before (purple) and after (red)
the introduced mutation for each variant functionally validated in the mini-gene splicing
assay. In silico predictions suggest all mutations strengthen the alternative splice site.
(E) Candidate splice-site-creating mutations validated by the mini-gene splicing assay.
Exons of interest were cloned into the pCAS2.1 vector and mutant (red); wild-type (purple)
plasmids were transfected into 293T cells; and total RNA was extracted to identify mutationinduced alternatively spliced products.
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Figure 6. Schematic of GATA3 Splice-Site-Creating Mutations and Neoantigen Predictions
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(A) Distribution of neoantigens predicted by NetMHCpan and NetMHC4. Genes with the
highest number of neoantigens labeled. Mean value for each tool indicated by X and labeled.
(B) Genes with the largest recurrence of predicted neoantigens across the dataset. GATA3
shows the highest recurrence.
(C) Mutual exclusivity of protein-affecting mutation (PAM), frameshifting indel (FS), inframe indel (IF), and splice-site-creating mutations (SCM) in GATA3. (D) IGV screenshot
of GATA3 splice-site-creating mutation, which disrupts the canonical splice site and utilizes
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a cryptic splice site 7 bp downstream. Mutant reads highlighted in red, and normal reads are
in purple. CA deletion indicated in the figure.
(E) Predicted functional domains disrupted because of the recurrent splice-site-creating
mutation in GATA3.
(F) Predicted neoantigen peptide sequences mapped to the frameshifted protein product for
samples with GATA3 SCMs.
(G) Mass spectrum of GATA3 peptide in TCGA-AR-A1AP.
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Figure 7. PD-L1, PD-L2, PD-1, CD8A, and CD8B Expression
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(A) Expression comparison of PD-L1, PD-L2, and T cell markers PD-1, CD8A, and CD8B
between samples with (case) and without (control) SCMs across six cancer types. p values: *
less than 0.05; ** < 0.01; and *** < 0.001; ns, not significant.
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REAGENT or RESOURCE

SOURCE

IDENTIFIER

ATCC

https://www.atcc.org/products/all/CRL-3216.aspx

Primers for cDNA amplification pCASKO1-(5′TGACGTCGCCGCCCATCAC-3′) pCASR (5′ATTGGTTGTTGAGTTGGTTGTC-3′)

This paper

N/A

Primers for Q5 mutagenesis and restriction
enzyme primers for amplifying exons of
interest see Table S6

This paper

N/A

Inserm Laboratory

N/A

MaxEntScan

Yeo and Burge, 2004

http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html

Samtools

Li et al., 2009

http://samtools.sourceforge.net/

MiSplice

In preparation

https://github.com/ding-lab/misplice

Integrative Genomics Viewer

Robinson et al., 2011

http://software.broadinstitute.org/software/igv/

Nucleospin PCR Cleanup

Macherey-Nagel

740609.10

DNA Clean and Concentrator-5 Kit

Zymo Research

D4003

BamHI

New England Biomedicine

R0136S

MluI

New England Biomedicine

R0198S

T4 DNA Ligase

New England Biomedicine

M0202S

Q5 Site Directed Mutagenesis

New England Biomedicine

E0554S

Lipofectamine 2000

Thermofisher Scientific

12566014

Superscript III First-Strand Synthesis
System

Thermofisher Scientific

18080051

Qiaquick Gel Extraction Kit

QIAGEN

28704

Public MC3 MAF

In preparation

https://gdc.cancer.gov

MSGF+

N/A

https://www.ncbi.nlm.nih.gov/pubmed/?term=25358478

Mass Spectra Data from 77 TCGA Breast
Cancer Patients

N/A

https://cptac-data-portal.georgetown.edu/cptac/s/S029

Experimental Models: Cell Lines
Human: HEK293T cells
Oligonucleotides

Recombinant DNA
Plasmid: pCAS2
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Software and Algorithms

Chemicals, Peptides, and Recombinant
Proteins
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